VIDEO: Positive trial results on selective estrogen receptor degrader 'exciting'

ByErin Michael

Add topic to email alerts

Please provide your email address to receive an email when new articles are posted on Breast Cancer.

Ian E. Krop, MD, PhD, associate chief of the division of breast oncology in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, spoke with Healio about a recent study on elacestrant.

Results from the EMERALD trial — which assessed elacestrant (Menarini Group/Radius Health) in patients with ER-positive, HER2-negative advanced or metastatic breast cancer — were presented at this year’s San Antonio Breast Cancer Symposium.

Krop explained that the study showed superior efficacy with elacestrant, a selective estrogen receptor degrader (SERD), compared with standard-of-care endocrine therapy.

He said that “having this first randomized trial being a positive trial is exciting,” not just for elacestrant itself, “but the fact that there’s a number of other SERDs in development is good news for patients since we haven’t had a new endocrine therapy in 20-plus years.”

References:

Bardia A, et al. Abstract GS2-02. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.

Published by:

Sources/Disclosures

Collapse

Source: Healio Interview

Disclosures: Krop reports salary from AMAG Pharmaceuticals and Freeline Therapeutics; consulting fees from AstraZeneca, Bristol-Myers Squibb, Context Therapeutics, Daiichi Sankyo, Genentech/Roche, Ionis Pharmaceuticals/Novartis, Macrogenics, Merck, Seattle Genetics and Taiho Pharmaceutical; contracted research from Genentech and Pfizer; ownership interest in AMAG Pharmaceuticals, Freeline Therapeutics and Vertex; receiving honoraria from AstraZeneca, Celltrion and Genentech/Roche; and serving in leadership roles with AMAG Pharmaceuticals and Freeline Therapeutics.